News
PRPO
26.00
+2.93%
0.74
Weekly Report: what happened at PRPO last week (0629-0703)?
Weekly Report · 2d ago
The Zacks Analyst Blog Highlights Caterpillar, Palo Alto Networks, Toyota Motor and Precipio
NASDAQ · 06/29 14:57
Weekly Report: what happened at PRPO last week (0622-0626)?
Weekly Report · 06/29 09:50
Top Analyst Reports for Caterpillar, Palo Alto & Toyota
NASDAQ · 06/26 20:16
Weekly Report: what happened at PRPO last week (0615-0619)?
Weekly Report · 06/22 09:56
Precipio Shareholders Back Board Nominees and Auditor
TipRanks · 06/15 21:22
Precipio shareholders approve director slate at annual meeting
PUBT · 06/15 20:01
Weekly Report: what happened at PRPO last week (0608-0612)?
Weekly Report · 06/15 09:57
Precipio announces annual shareholder meeting
PUBT · 06/12 17:00
Precipio is requesting Shareholders/Brokers vote today to avoid costly adjournment and rescheduling of Annual Shareholders Meeting
Barchart · 06/12 12:00
Precipio to present at Planet MicroCap Las Vegas 2026 conference
PUBT · 06/11 21:00
Weekly Report: what happened at PRPO last week (0601-0605)?
Weekly Report · 06/08 09:54
Weekly Report: what happened at PRPO last week (0525-0529)?
Weekly Report · 06/01 09:57
Precipio Insider Makes Notable Move With Fresh Stock Sale
TipRanks · 05/27 02:02
Precipio director Richard A. Sandberg sells 900 shares worth $22,517.37
PUBT · 05/26 20:01
Weekly Report: what happened at PRPO last week (0518-0522)?
Weekly Report · 05/25 09:59
Precipio Stock Slips Post Q1 Earnings Despite Revenue Growth
NASDAQ · 05/22 14:27
Precipio Insider Makes Bold Move With Significant Stock Sale
TipRanks · 05/22 02:06
Precipio director Richard Sandberg disposes of common shares worth $77,009.68
PUBT · 05/21 20:00
Precipio Earnings Call Balances Growth And Margin Pressures
TipRanks · 05/20 05:32
More
Webull provides a variety of real-time PRPO stock news. You can receive the latest news about Precipio Inc through multiple platforms. This information may help you make smarter investment decisions.
About PRPO
Precipio, Inc. is a healthcare biotechnology company that is focused on cancer diagnostics. The Company’s technologies include HemeScreen and IV-Cell. The HemeScreen panels test for the presence of various mutations. In developing HemeScreen, it focused on improving the economics of providing blood cancer diagnostic tests and reducing laboratory technician time consumed in the testing process. Its technology enables testing to be completed in one rapid scanning process. IV-Cell is a cell culture media that addresses the problem of diagnostic mistakes through the process of selective culturing. IV-Cell is a universal media that enables simultaneous culturing of all four hematopoietic cell lineages. Its product category includes Molecular Kits and IV-Cell Cytogenetics Media. The Molecular Kits include Quantitative MPN Panel, ABL1 Resistance Panel, and others. The Company’s laboratory and research and development (R&D) facilities are located in New Haven, Connecticut and Omaha, Nebraska.